Promis­ing or in­con­clu­sive? Gilead fields PhII GS-4997 da­ta, trig­ger­ing more push­back on NASH claims

Gilead post­ed a de­tailed snap­shot of Phase II ef­fi­ca­cy da­ta for GS-4997, now known as selon­sert­ib, for NASH and liv­er fi­bro­sis, trig­ger­ing a mixed re­sponse of en­thu­si­asm and some clear skep­ti­cism from the an­a­lysts watch­ing this late-stage drug, some of whom got their first crack in when Gilead out­lined the top line da­ta from this study in Oc­to­ber.

The num­bers were de­tailed for selon­sert­ib alone, in com­bi­na­tion with sim­tuzum­ab or in sim­tuzum­ab alone. And in­ves­ti­ga­tors had a mixed bag of re­sults un­der­scor­ing drug ac­tiv­i­ty, rang­ing from the 43% of pa­tients tak­ing selon­sert­ib see­ing an im­prove­ment in fi­bro­sis com­pared to the 20% in the sim­tuzum­ab arm to the 20% in the selon­sert­ib arm ex­pe­ri­enc­ing a min­i­mum 15% re­duc­tion in liv­er stiff­ness to the 32% in the com­bo group and none tak­ing sim­tuzum­ab alone.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER